Skip to main content
Contact Us
Subscribe
E-Edition
28°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Natera Inc
(NQ:
NTRA
)
171.65
+2.63 (+1.56%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Natera Inc
< Previous
1
2
3
4
5
6
7
Next >
Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology
December 02, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
November 27, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
November 25, 2024
From
Natera, Inc.
Via
Business Wire
Natera Issues Statement on Guardant Health Litigation
November 25, 2024
From
Natera, Inc.
Via
Business Wire
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year
November 25, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
November 21, 2024
From
Natera, Inc.
Via
Business Wire
Natera Reports Third Quarter 2024 Financial Results
November 12, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
November 12, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Participate in Upcoming Investor Conferences
November 08, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Report its Third Quarter 2024 Results on November 12, 2024
November 01, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Present New Renasight Data at ASN Kidney Week 2024
October 22, 2024
From
Natera, Inc.
Via
Business Wire
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
September 23, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
September 16, 2024
From
Natera, Inc.
Via
Business Wire
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
September 14, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
September 08, 2024
From
Natera, Inc.
Via
Business Wire
Natera Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 06, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Report its Second Quarter 2024 Results on August 8, 2024
July 30, 2024
From
Natera, Inc.
Via
Business Wire
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
July 26, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
July 03, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
June 27, 2024
From
Natera, Inc.
Via
Business Wire
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
June 18, 2024
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including
Via
MarketBeat
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
June 17, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Natera, Inc.
Via
Business Wire
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
May 30, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
May 23, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
May 23, 2024
From
Natera, Inc.
Via
Business Wire
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 14, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Natera Reports First Quarter 2024 Financial Results
May 09, 2024
From
Natera, Inc.
Via
Business Wire
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
May 03, 2024
From
Natera, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.